Evidence map›Paper›PMID 31277325›Full record

ArticleVaccines2019

RSV Vaccine Based on Rhabdoviral Vector Protects after Single Immunization.

Sarah Wilmschen, Sabrina Schneider, Felix Peters, Lea Bayer, Leila Issmail, Zoltán Bánki, Thomas Grunwald, Dorothee von Laer, Janine Kimpel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sarah WilmschenDivision of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Sabrina SchneiderDivision of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Felix PetersDivision of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Lea BayerDepartment of Immunology, Fraunhofer Institute for Cell Therapy and Immunology IZI, 04103 Leipzig, Germany.
Leila IssmailDepartment of Immunology, Fraunhofer Institute for Cell Therapy and Immunology IZI, 04103 Leipzig, Germany.
Zoltán BánkiDivision of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Thomas GrunwaldDepartment of Immunology, Fraunhofer Institute for Cell Therapy and Immunology IZI, 04103 Leipzig, Germany.
Dorothee von LaerDivision of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Janine KimpelDivision of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria. Janine.kimpel@i-med.ac.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The respiratory syncytial virus (RSV) is one major cause of lower respiratory tract infections in childhood and an effective vaccine is still not available. We previously described a new rhabdoviral vector vaccine, VSV-GP, a variant of the vesicular stomatitis virus (VSV), where the VSV glycoprotein G is exchanged by the glycoprotein GP of the lymphocytic choriomeningitis virus. Here, we evaluated VSV-GP as vaccine vector for RSV with the aim to induce RSV neutralizing antibodies. Wild-type F (F

Indexed as

neutralizing antibodiesrespiratory syncytial virus (RSV)viral vector vaccineVSV-GP

Identifiers

PMID31277325
PMCPMC6790003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.